Engineered blood has the greatest potential to combat a predicted future shortfall in the blood supply for transfusion treatment. The production of red blood cells from hematopoietic stem cells in the laboratory is possible but the mass production of red blood cells to the level present in a blood transfusion unit is currently not possible. The proliferation capacity of the immature red blood cell will need to be increased to enable mass production. This work focused on the hypothesis that exogenous c-Myc can delay the differentiation process of highly proliferative immature erythroblasts, and increase the proliferation capacity of erythroblast cell cultures.

中文翻译：

---

外源性c-Myc阻滞分化并改善体外人类成纤维细胞的扩增。

工程血液具有最大的潜力，可以应对输血治疗中预期的未来血液供应短缺。在实验室中可以从造血干细胞生产红细胞，但目前尚无法将红细胞大规模生产到输血单元中的水平。未成熟的红细胞的增殖能力将需要增加以能够大量生产。这项工作侧重于这样的假设，即外源性c-Myc可以延迟高度增殖的未成熟成血细胞的分化过程，并增加成血细胞细胞培养物的增殖能力。